Methods of using krill oil to treat risk factors for cardiovascular, metabolic, and inflammatory disorders
This invention discloses methods of using krill oil and compositions comprising krill oil to treat risk factors for metabolic, cardiovascular, and inflammatory disorders. The present invention also relates to methods of using compositions comprising krill oil to modulate biological processes selected from the group consisting of glucose metabolism, lipid biosynthesis, fatty acid metabolism, cholesterol biosynthesis, and the mitochondrial respiratory chain. The present invention further includes pharmaceutical and/or nutraceutical formulations made from krill oil, methods of making such formulations, and methods of administering them to treat risk factors for metabolic, cardiovascular, and inflammatory disorders.
1. A method for reducing risk factors for metabolic disorders in a subject, comprising: administering to said subject an effective amount of a krill oil composition, said krill oil composition comprising from about 40% w/w to about 60% w/w phospholipids, wherein said phospholipids comprise about 1% to 8% ether phospholipids, and about 25% to 45% triglycerides, under conditions such that metabolic disease risk factors of the subject are improved, wherein the metabolic disease risk factor improvements are selected from the group consisting of a reduction in ectopic fat; an increase in the levels of EPA and DHA in the phospholipid fractions of tissues that exhibit changes in endocannabinoid concentration upon administration of said krill oil composition; a reduction in monoacylglyceride lipase activity in the visceral adipose tissue; an increase in the level of plasma ALA/LA; and a decrease in the level of ARA in the subcutaneous adipose tissue.
2. The method of claim 1 , wherein the metabolic disorders are selected from the group consisting of type II diabetes, obesity, and metabolic syndrome.
3. The method of claim 1 , wherein said metabolic disease risk factor improvement is a reduction in ectopic fat upon administration of said krill oil composition.
4. The method of claim 1 , wherein said metabolic disease risk factor improvement is an increase the levels of EPA and DHA in the phospholipid fractions of tissues that exhibit changes in endocannabinoid concentration upon administration of said krill oil composition.
5. The method of claim 1 , wherein said metabolic disease risk factor improvement is a reduction in monoglyceride lipase activity in the visceral adipose tissue upon administration of said krill oil composition.
6. The method of claim 1 , wherein said metabolic disease risk factor improvement is an increase in the level of plasma ALA/LA upon administration of said krill oil composition.
7. The method of claim 1 , wherein said metabolic disease risk factor improvement is a decrease in the level of ARA in the subcutaneous adipose tissue upon administration of said krill oil composition.